Business Wire

NY-CITI-GLOBAL-WEALTH

9.12.2021 22:32:08 CET | Business Wire | Press release

Share
Citi Global Wealth Investments Releases Outlook 2022: The Expansion Will Endure: Seeking Sustained Returns

Citi Global Wealth Investments today released its Outlook 2022 report, titled The expansion will endure: Seeking sustained returns . Released twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond, also highlighting transformational, multi-year “unstoppable trends” across markets.

The latest edition suggests that the strongest phase of the economic and market recovery from the pandemic is likely behind us. More normal conditions lie ahead following the “great rebound,” with more moderate returns as the equity bull market matures. But rather than leaving portfolios as they are, Citi believes this normalization calls for investors to make important asset allocation changes.

Going into 2021, Citi recommended positioning for a snapback in many assets that had been hit hardest by the pandemic. These included emerging markets, small-cap equities and beaten-down cyclicals. For 2022 and beyond, by contrast, Citi emphasizes exposure to “long-term leaders,” equities in high-quality companies in expanding industries that may deliver earnings growth in the long run. Historical analysis shows that long-term leaders have delivered strong returns with lower volatility over time. Examples include “dividend growers,” equities in companies with long records of increasing their dividends.

With inflation up but bond yields remaining low, Citi is reiterating the threat that negative real interest rates pose to wealth. “As we warned in last year’s report, the owners of cash and many bonds have suffered a loss of purchasing power in 2021,” said David Bailin, Chief Investment Officer and Head of Citi Global Wealth Investments . “We compare the effect of negative real rates to the activities of a cash thief, who we expect to remain at large in 2022. But we see various investments that may help clients preserve and grow purchasing power in the face of this threat.”

Citi has also identified “unstoppable trends” that are reshaping business and everyday life, as well as portfolios. These include multiple aspects of digitization such as cybersecurity, 5G and related technologies and fintech, as well as the ongoing shift of economic power towards Asia. In each of these areas, the pandemic has accelerated change. New working patterns, for example, are transforming the demand for offices, while the growth of online retail is intensifying the need for warehouse and delivery facilities.

“While we reiterate the importance of keeping portfolios positively positioned and fully invested, we also acknowledge a range of risks,” said Steven Wieting, Chief Investment Strategist and Chief Economist at Citi Global Wealth Investments . “The potential for vaccine-resistant COVID mutations, deteriorating U.S.-China relations, large-scale cyberattacks and evolving consumer spending habits based on inflation expectations all require close monitoring.”

With the economic expansion set to endure, we see the potential for further upside in financial markets. After a 45% rise in 2021, global earnings per share may increase by a more normal 8% in 2022. Global equities might deliver a mid-to-high single-digit return in this environment, with global fixed income returning 0% to 1% before inflation.

The full report, a summary version, short videos and other materials can be accessed here .

Announced in January 2021, Citi Global Wealth (“CGW”) is comprised of the wealth management businesses of Citi Private Bank and Citi’s Global Consumer Bank. Through these businesses, CGW delivers Citi’s wealth solutions, products and services globally. The unified management and delivery of CGW’s wealth strategy represents a further commitment by Citi to become a leading global wealth business. Citi Global Wealth Investments (“CGWI”) is comprised of the Investments and Capital Markets capabilities of Citi Private Bank, Citi Personal Wealth Management and International Personal Bank U.S.

About Citi:
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management. Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye